Big effect
Vitamin D lowered a key inflammation marker by 39% in a 12-week trial — but only in colorectal cancer patients with low starting levels.
This striking drop in interleukin-6 is promising for reducing inflammation in a clinical setting, though the broader evidence for vitamin D's anti-inflammatory effects is mixed, and the same study found no benefit for two other inflammatory markers.
In a double-blind trial, colorectal cancer patients with low vitamin D status received a personalized loading dose followed by 2,000 IU daily for 12 weeks. Their blood levels of interleukin-6 — a protein involved in chronic inflammation — fell by 39% relative to placebo. However, two other inflammation-related markers did not budge, and the results may not apply to healthy people or those with sufficient vitamin D.
Where this fits in the evidence
Pillser has synthesized 8 studies on Vitamin D for Reduced Interleukin-6 Levels — overall evidence strength: Moderate.
Across 8 studies, 5 reported beneficial effects (4 statistically significant) and 3 reported neutral effects, with no harmful findings. The predominant effect size is small to moderate, with the most robust evidence coming from RCTs showing moderate effects in clinical populations (e.g., colorectal cancer patients, overweight/obese adults). Doses ranged from 200 IU/day to personalized loading doses, and the median study duration was 56 days, indicating effects typically observed at 8–12 weeks.
The study
- Randomized Controlled Trial (RCT)
- n = 126
- 2026-01-08
- British journal of cancer
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.